Press Releases

• Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy Is Well Tolerated In A Pilot Study Of Immunocompromised Patients With Influenza A — April 28, 2010
• Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models — March 15, 2010
• Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy Is More Potent Than Double Combinations Or Monotherapy Against Drug-Resistant Flu Strains — February 22, 2010
• Adamas Pharmaceuticals Expands Clinical Study For Triple-Combination Antiviral Drug Therapy In Immune-Compromised Patients — November 19, 2009
• In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses — September 13, 2009
• Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting — September 3, 2009
• Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions — August 25, 2009
• Adamas Pharmaceuticals Raises $40 Million in Series D Financing — August 18, 2009
• Adamas Pharmaceuticals Signs CRADA with U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including The Novel H1N1 Pandemic Strain — August 18, 2009

Back to top »